Tissue distribution of liposome-mediated epidermal growth factor receptor antisense gene therapy

Cancer Gene Therapy

Volumn 10, Issue 7, 2003, Pages 518-528

  Thomas, Sufi M ^a   Zeng, Qing ^a   Dyer, Kevin F ^a   Suscovich, Todd J ^a,c   Kanter, Peter M ^b   Whalen, Janey D ^a   Watkins, Simon F ^c   Grandis, Jennifer Rubin ^a,d  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^c ROSWELL PARK CANCER INSTITUTE   (United States)

^d University of Pittsburgh School of Medicine   (United States)

Author keywords

Antisense gene therapy; Epidermal growth factor receptor; Head and neck squamous cell carcinoma; Tissue distribution

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GENOMIC DNA; LIPOSOME; PLASMID DNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOASSAY; CONTROLLED STUDY; FEMALE; GENE THERAPY; GENOME; HEAD AND NECK CANCER; IMAGE ANALYSIS; INTERMETHOD COMPARISON; MALE; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SOUTHERN BLOTTING; TISSUE DISTRIBUTION;

ANIMALS; BASE SEQUENCE; CARCINOMA, SQUAMOUS CELL; FEMALE; GENE THERAPY; GENETIC VECTORS; HEAD AND NECK NEOPLASMS; HUMANS; LIPOSOMES; MALE; MICE; MICE, INBRED ICR; MOLECULAR SEQUENCE DATA; NEOPLASMS; OLIGONUCLEOTIDES, ANTISENSE; PLASMIDS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TISSUE DISTRIBUTION; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

ANIMALIA;

EID: 0037818323     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700567     Document Type: Article

References (33)

1. Vokes EE, Weichselbaum RR, Lippman SM, et al. Head and neck cancer. N Engl J Med. 1993;328:184-194.
2. Forastiere AA. Head and neck cancer: overview of recent developments and future directions. Semin Oncol. 2000;27:1-4.
3. Grandis JR, Melhem MF, Gooding WE, et al. Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival [see comments]. J Natl Cancer Inst. 1998;90:824-832.
4. Lango MN, Shin DM, Grandis JR. Targeting growth factor receptors: integration of novel therapeutics in the management of head and neck cancer. Curr Opin Oncol. 2001;13:168-175.
5. Rubin Grandis J, Chakraborty A, Melhem MF, et al. Inhibition of epidermal growth factor receptor gene expression and function decreases proliferation of head and neck squamous carcinoma but not normal mucosal epithelial cells. Oncogene. 1997;15:409-416.
6. He Y, Zeng Q, Drenning SD, et al. Inhibition of human squamous cell carcinoma growth in vivo by epidermal growth factor receptor antisense RNA transcribed from the U6 promoter. J Natl Cancer Inst. 1998;90:1080-1087.
7. Zeng Q, KP, Dhir R, et al. Lack of toxicity of egfr antisense gene therapy. Exp Ther Oncol. 2001 (in press).
8. Stewart MJ, Plautz GE, Del Buono L, et al. Gene transfer in vivo with DNA-liposome complexes: safety and acute toxicity in mice. Hum Gene Ther. 1992;3:267-275.
9. Nabel GJ, Nabel EG, Yang ZY, et al. Direct gene transfer with DNA-liposome complexes in melanoma: expression, biologic activity, and lack of toxicity in humans. Proc Nat Acad Sci USA. 1993;90:11307-11311.
10. Lew D, Parker SE, Latimer T, et al. Cancer gene therapy using plasmid DNA: pharmacokinetic study of DNA following injection in mice [see comments]. Hum Gene Ther. 1995;6:553-564.
11. Xing X, Zhang S, Chang JY, et al. Safety study and characterization of E1A - liposome complex gene-delivery protocol in an ovarian cancer model. Gene Therapy. 1998;5:1538-1544.
12. Sorgi FL, Bhattacharya S, Huang L. Protamine sulfate enhances lipid-mediated gene transfer. Gene Therapy. 1997;4:961-968.
13. Sacks PG, Parnes SM, Gallick GE, et al. Establishment and characterization of two new squamous cell carcinoma cell lines derived from tumors of the head and neck. Cancer Res. 1988;48:2858-2866.
14. Southern EM, Mitchell AR. Chromatography of nucleic acid digests on thin layers of cellulose impregnated with polyethyleneimine. Biochem J. 1971;123:613-617.
15. Clayman GL, Frank DK, Bruso PA, et al. Adenovirus-mediated wild-type p53 gene transfer as a surgical adjuvant in advanced head and neck cancers. Clin Cancer Res. 1999;5:1715-1722.
16. Lamont JP, Nemunaitis J, Kuhn JA, et al. A prospective phase II trial of ONYX-015 adenovirus and chemotherapy in recurrent squamous cell carcinoma of the head and neck (the Baylor experience). Ann Surg Oncol. 2000;7:588-592.
17. Khuri FR, Shin DM, Glisson BS, et al. Treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck: current status and future directions. Semin Oncol. 2000;27:25-33.
18. Gleich LL, Gluckman JL, Armstrong S, et al. Alloantigen gene therapy for squamous cell carcinoma of the head and neck: results of a phase-1 trial. Arch Otolaryngol Head Neck Surg. 1998;124:1097-1104.
19. Wollenberg B, Kastenbauer, Mundl H, et al. Gene therapy - phase I trial for primary untreated head and neck squamous cell cancer (HNSCC) UICC stage II-IV with a single intratumoral injection of hIL-2 plasmids formulated in DOTMA/Chol. Hum Gene Ther. 1999;10:141-147.
20. Yoo GH, Hung MC, Lopez-Berestein G, et al. Phase I trial of intratumoral liposome E1A gene therapy in patients with recurrent breast and head and neck cancer. Clin Cancer Res. 2001;7:1237-1245.
21. Yu D, Matin A, Xia W, et al. Liposome-mediated in vivo E1A gene transfer suppressed dissemination of ovarian cancer cells that overexpress HER-2/neu. Oncogene. 1995;11:1383-1388.
22. Caplen NJ, Kinrade E, Sorgi F, et al. In vitro liposome-mediated DNA transfection of epithelial cell lines using the cationic liposome DC-Chol/DOPE. Gene Therapy. 1995;2:603-613.
23. Caplen NJ, Alton EW, Middleton PG, et al. Liposome-mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis. Nat Med. 1995;1:39-46.
24. Gao X, Huang L. A novel cationic liposome reagent for efficient transfection of mammalian cells. Biochem Biophys Res Commun. 1991;179:280-285.
25. He Y, Q Z, SD D, et al. EGFR antisense RNA transcribed from the U6 promotor inhibits human squamous cell carcinoma growth in vivo. Natl Cancer Inst. 1998;90:1080-1087.
26. Good PD, Krikos AJ, Li SX, et al. Expression of small, therapeutic RNAs in human cell nuclei. Gene Therapy. 1997;4:45-54.
27. Svensson EC, Tripathy SK, Leiden JM. Muscle-based gene therapy: realistic possibilities for the future. Mol Med Today. 1996;2:166-172.
28. Levy MY, Barron LG, Meyer KB, et al. Characterization of plasmid DNA transfer into mouse skeletal muscle: evaluation of uptake mechanism, expression and secretion of gene products into blood. Gene Therapy. 1996;3:201-211.
29. Wolff JA, Ludtke JJ, Acsadi G, et al. Long-term persistence of plasmid DNA and foreign gene expression in mouse muscle. Hum Mol Genet. 1992;1:363-369.
30. Thierry AR, Lunardi-Iskandar Y, Bryant JL, et al. Systemic gene therapy: biodistribution and long-term expression of a transgene in mice. Proc Natl Acad Sci USA. 1995;92:9742-9746.
31. Ledley FD. Nonviral gene therapy: the promise of genes as pharmaceutical products. Hum Gene Ther. 1995;6:1129-1144.
32. Manthorpe M, Cornefert-Jensen F, Hartikka J, et al. Gene therapy by intramuscular injection of plasmid DNA: studies on firefly luciferase gene expression in mice. Hum Gene Ther. 1993;4:419-431.
33. Hengge UR, Dexling B, Mirmohammadsadegh A. Safety and pharmacokinetics of naked plasmid DNA in the skin: studies on dissemination and ectopic expression. J Invest Dermatol. 2001;116:979-982.